ClinicalTrials.gg
Not yet recruitingNCT05161637Updated Apr 11, 2024

Phase 2/3 Study of TLC590 for Postsurgical Pain Management

A Phase 2/3 interventional study of TLC590 and Bupivacain in Postsurgical Pain Management, sponsored by Taiwan Liposome Company. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-11.

Sponsored by Taiwan Liposome Company · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
415
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 184 studies testing ropivacaine in Pain, Postoperative — 20 open to participants now, 22 under way, 2 of them phase 3. Ropivacaine · Pain, Postoperative.

Planned enrollment
Largest of 184
415 · median 70
Started
2025
with 5 others
Phase 2/3
Only one
of the 184
Primary completion
2025-12
later than 5 of 21 live
Registered
151st of 184
by date

Among the 184 studies testing ropivacaine in Pain, Postoperative, this one has the largest planned enrollment, is one of 6 that started in 2025, is the only one in phase 2/3, reaches primary completion later than 5 of the 21 other live ones, and was the 151st registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

20 of the 184 studies testing ropivacaine in Pain, Postoperative are open now, in 10 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About ropivacaine

Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies testing ropivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

A phase 2/3 randomized, double-blind, 2-part, comparator- and placebo-controlled study to assess the safety, pharmacokinetics and efficacy of postsurgical local infiltration in adult subjects following inguinal hernia repair surgery.

Read the detailed description

This is a phase 2/3 randomized, double-blind, 2-part, comparator- and placebo-controlled study to assess the safety, pharmacokinetics and efficacy of postsurgical local infiltration in adult subjects following inguinal hernia repair surgery. This study includes 2 parts. An unblinded interim analysis will be performed after completion of part 1 (phase 2, approximately 115 subjects to be randomized for 2 different doses of TLC590, bupivacaine, ropivacaine, or placebo), for selecting a TLC590 dose for part 2 (phase 3, approximately 300 subjects to be randomized for TLC590, bupivacaine, or placebo).In this study, 2 doses of TLC590 24.5 mg/mL in inguinal hernia repair will be assessed in an initial phase 2 part before proceeding to a phase 3 pivotal evaluation.

03

Conditions studied

  • Postsurgical Pain Management

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female at least 18 years old
  • 18-39 kg/m2
  • Scheduled to undergo a primary, unilateral Lichtenstein inguinal hernia repair with mesh
  • ASA Physical Status Classification of 1, 2 or 3

Exclusion criteria

Exclusion Criteria:

  • abnormal clinical laboratory test value
  • Clinically significant 12-lead
  • History of orthostatic hypotension or syncope
  • History of significant renal, hepatic, gastrointestinal, cardiovascular, metabolic, neurologic, psychiatric, or other condition
  • History of seizure or currently taking anticonvulsants
  • History of to bupivacaine/ropivacaine, any other amide-type local anesthetic, propofol, oxycodone or morphine (or other opioids)
  • History of severe or post-operative nausea or vomiting (PONV)
  • Abnormalities of laboratory parameters: , , , WBC, serun //aspartate aminotrasferase, serum creatinine, /INR
  • Concurrent acute, or chronic painful restrictive/physical condition
  • Received opioid therapy for longer than 4 days per week
  • Prohibited medication: aspirin and other anti-platelet medication, anticoagulants, class III antiarrhythmic drugs, strong CYP1A2 inhibitors,systemic , NSAID, opioid, bupivacaine or ropivacaine, any product
  • History of drug abuse or alcohol abuse
  • Positive results on the urine drug screen or alcohol breath test
  • History of ; active or
  • An inguinal hernia repair in the last 3 months or has undergone 3 or more surgeries within 12 months
  • in the last 2 years
  • Documented sleep apnea or on home continuous positive airway pressure treatment (CPAP)
  • Personal or family history of malignant hyperthermia.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
415 participants (estimated)

Study arms

  • Experimental
    TLC590 490mg

    TLC590 490mg (20mL)

    Drug: TLC590

  • Experimental
    TLC590 588mg

    TLC590 588mg (24mL)

    Drug: TLC590

  • Active comparator
    Bupivacaine 75mg

    Bupivacaine HCl 75mg (30mL)

    Drug: Bupivacain

  • Active comparator
    Ropivacaine

    Ropivacaine HCl 150mg (30mL) (Part 1)

    Drug: Ropivacaine

  • Placebo comparator
    Normal saline

    Normal Saline 0.9% (20mL or 24mL)

    Drug: Normal saline

Interventions

  • DrugTLC590

    TLC590 490mg or 588mg

    Also known as: intestigational drug

  • Bupivacaine 75mg

    Also known as: active comparator

  • Ropivacaine 150mg

    Also known as: active comparator

  • DrugNormal saline

    Normal saline 20mL or 24mL

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. Part 1 - AUC 0-24 of NPRS-M

    AUC 0-24 of NPRS-M, evaluated comparing each dose of TLC590 with Placebo

    Time frame: 0-24 hours

  2. Part 2 - AUC 0-72 of NPRS-M

    AUC 0-72 of NPRS-M, evaluated comparing each dose of TLC590 with Placebo

    Time frame: 0-72 hours

Secondary outcomes

  1. AUC 0-72 of NPRS-M (active comparator)

    AUC 0-72 of NPRS-M (TLC590 vs Bupivacaine)

    Time frame: 0-72 hours

  2. Proportion of opioid-free subjects through 72 hours (placebo)

    Proportion of opioid-free subjects through 72 hours (TLC590 vs. Placebo)

    Time frame: 0-72 hours

  3. Proportion of opioid-free subjects through 72 hours (active comparator)

    Proportion of opioid-free subjects through 72 hours (TLC590 vs. Bupivacaine)

    Time frame: 0-72 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Dec 2025, 8 months later.

Of 52 phase 2/3 interventional studies under Pain, Postoperative, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2021
First posted
Dec 17, 2021
StartEst.
Apr 2025
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Apr 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05161637
Lead sponsor
Taiwan Liposome Company
Responsible party
Sponsor
First posted
Dec 17, 2021
Start date
Apr 2025 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Apr 11, 2024

Study contacts

Grace Tsao
Contact
grace@tlcbio.com
+886-2-26557377
Terry Tai, PhD
study director · Taiwan Liposome Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion